Key result
Concomitant treatment with proton pump inhibitors did not attenuate the antiplatelet effect of clopidogrel across 5 platelet function tests in patients on dual antiplatelet therapy (all P>0.05).
Why the study?
Does concomitant proton pump inhibitor therapy attenuate the antiplatelet effect of clopidogrel in patients on dual antiplatelet therapy after angioplasty and stenting?
Population
230 patients on dual antiplatelet therapy after angioplasty and stenting for cardiovascular disease
Comparison
Proton pump inhibitors including pantoprazole… vs No PPI therapy (n=95)
Design
Cohort
Authors
Loading...
May support PPI co-prescription with clopidogrel; leaves open translation to clinical outcomes in stented patients.
Observational (n=230)
Does concomitant proton pump inhibitor therapy attenuate the antiplatelet effect of clopidogrel in patients on dual antiplatelet therapy after angioplasty and stenting?
p-value: p=>0.05
Concomitant use of proton pump inhibitors does not significantly attenuate the antiplatelet efficacy of clopidogrel in patients undergoing angioplasty and stenting, regardless of the PPI type or platelet function assay used.
Gremmel et al. (2010) conducted an observational in Cardiovascular disease (n=230). Proton pump inhibitors (PPIs) vs. No PPI therapy was evaluated on ADP-inducible platelet reactivity (p=>0.05). Concomitant treatment with proton pump inhibitors did not attenuate the antiplatelet effect of clopidogrel across 5 platelet function tests in patients on dual antiplatelet therapy (all P>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: